News

conference

Nov 9, 2024

2024 - SITC

Doxorubicin-based click chemistry therapeutic activates potent cytotoxic immune responses in advanced sarcoma patients in a Phase 1/2a clinical trial

conference

Nov 9, 2024

2024 SITC

Attenuated MMAE therapeutic activated by click chemistry at the tumor evokes potent immune responses

conference

Nov 4, 2024

2024 World ADC

Pre-targeting with in vivo Click Chemistry Enables Preferential Drug Exposure in Tumors versus Normal Tissues

conference

Nov 4, 2024

2024 World ADC

CEACAM5 is an Ideal Target for Click Chemistry Enabled Pre-Targeting

press

Oct 31, 2024

press release

Shasqi to present at World ADC and SITC conferences

conference

Oct 23, 2024

2024 - EORTC-NCI-AACR Symposium

Pre-Targeting with in vivo Click Chemistry Enables Preferential Drug Exposure in Tumors versus Normal Tissues

conference

Oct 10, 2024

2024 - World ADC

Shasqi presenting two sessions at World ADC 2024

conference

Oct 10, 2024

2024 - SITC

Shasqi announces two abstracts accepted for poster presentation at the SITC 39th Annual Meeting, held November 8-10, 2024, in Houston, TX

event

Aug 30, 2024

Event

Shasqi CEO, José Mejía Oneto, joining panel at LSX USA World Congress on September 11th, Boston

event

Aug 29, 2024

Event

Shasqi VP of Research Travis Biechele, PhD, presenting at ADC & Radiopharmaceuticals Pharma & Biotech Partner summit in Boston on September 9th

conference

Jun 1, 2024

2024 - ASCO

Shasqi presents Phase 2a results of SQ3370 in STS patients at ASCO 2024

conference

Apr 10, 2024

2024 - AACR

Improving anti-tumor efficacy by modulating a separate HER2 activator and an MMAE payload and reuniting both through click chemistry